TMPRSS2 and chronic myelogenous leukemia, BCR-ABL1 positive: In the field of cancer, some fusion genes are cancer driver events and can be used as biomarkers or even lead to effective treatment - for instance BCR-ABL1 in chronic myeloid leukemia (CML) [21] or TMPRSS2-ERG in prostate cancer [22, 23].